GlobeNewswire All Public CompaniesQwen · 实盘不做把握 9/10不做原因:不是事件
北京时间·🕒 发布 19:30:00·⟳ 抓取 19:33:21·⚡ 决策 09-01 19:34:23 +1m02s·56.1 天前
Pyxis Oncology宣布临时CEO将参加三场投资者会议，无新增实质信息
该公告为例行投资者会议参与通知，不含任何新增实质信息（无临床结果、无合作、无财务数据、无监管进展），不构成可交易催化。会议本身（9月10-14日）若产生新数据或重大声明，届时另行评估。
📄 原文GlobeNewswire All Public Companies↗ 原文
Pyxis Oncology to Participate in Upcoming Investor Conferences
BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing nex…
不做 Pyxis Oncology（PYXS.US）
例行投资者会议参与公告，不含任何新增实质信息（无临床数据、无合作、无财务指引、无监管进展），不构成交易催化，无方向、无edge
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Pyxis Oncology发布GlobeNewswire通稿，宣布临时CEO将参加三场投资者会议炉边对话。公告仅含会议时间地点和公司简介，无任何新增管线数据、合作关系、财务指引或监管信息。投资者会议参与公告是上市公司最常见的例行通讯之一，不改变任何基本面预期，不存在信息不对称或交易edge。
🔎 新鲜度:最早出现 2026-09-01 · 扩散 low · price-in 风险 low ↗
先例如何影响了这次决策
对本次决策的影响:无——事件无交易意义，先例研究不改变结论
方向:不适用——事件本身不构成催化，无需先例校准
涨幅量级:不适用
形态:不适用
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 681 ms
{"result": "search_processed_events:agent query=`pyxis oncology investor conference participation | pyxs fireside chat wells fargo cantor h.c. wainwright`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 62.0/72 小时、2128 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判。"}
原文全文
展开原文 · 2,540 字
BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Tom Civik, Interim Chief Executive Officer and Director of Pyxis Oncology, will participate in fireside chats at three upcoming conferences.
Wells Fargo 21
st
Annual Healthcare Conference
in Boston, MA on Thursday, September 10, 2026, at 10:15 a.m. ET.
2026 Cantor Global Healthcare Conference
in New York, NY on Friday, September 11, 2026, at 10:55 a.m. ET.
H.C. Wainwright 28
th
Annual Global Investment Conference
in New York, NY on Monday, September 14, 2026, at 9:30 a.m. ET.
Live webcasts and replays of the fireside chats will be available on the Events & Presentations page in the Investor Relations section of Pyxis Oncology’s website,
ir.pyxisoncology.com
.
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for difficult-to-treat cancers. The Company’s lead candidate, micvotabart pelidotin (MICVO), is a first-in-concept antibody-drug conjugate (ADC) that targets extradomain-B of fibronectin (EDB+FN), a non-cellular structural component of the tumor extracellular matrix (ECM). EDB+FN is selectively overexpressed in the tumor microenvironment of a wide range of solid tumors and largely absent from normal adult tissues. MICVO is designed to treat solid tumors through a three-pronged mechanism of action: direct cancer cell killing, bystander effect and immunogenic cell death. MICVO is currently being evaluated as monotherapy in a Phase 1 clinical study in patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) and in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in a Phase 1/2 clinical study in patients with R/M HNSCC and other solid tumors. Pyxis Oncology is focused on advancing MICVO, with the goal of improving outcomes for patients living with R/M HNSCC and contributing to meaningful progress in cancer treatment.
MICVO received Fast Track Designation from the U.S. Food and Drug Administration for the treatment of adult patients with R/M HNSCC whose disease has progressed following treatment with platinum-based chemotherapy and an anti-PD-(L)1 therapy.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
To learn more, visit
www.pyxisoncology.com
or follow us on
LinkedIn
.
Pyxis Oncology Contact
IR@pyxisoncology.com
Wells Fargo 21
st
Annual Healthcare Conference
in Boston, MA on Thursday, September 10, 2026, at 10:15 a.m. ET.
2026 Cantor Global Healthcare Conference
in New York, NY on Friday, September 11, 2026, at 10:55 a.m. ET.
H.C. Wainwright 28
th
Annual Global Investment Conference
in New York, NY on Monday, September 14, 2026, at 9:30 a.m. ET.
Live webcasts and replays of the fireside chats will be available on the Events & Presentations page in the Investor Relations section of Pyxis Oncology’s website,
ir.pyxisoncology.com
.
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for difficult-to-treat cancers. The Company’s lead candidate, micvotabart pelidotin (MICVO), is a first-in-concept antibody-drug conjugate (ADC) that targets extradomain-B of fibronectin (EDB+FN), a non-cellular structural component of the tumor extracellular matrix (ECM). EDB+FN is selectively overexpressed in the tumor microenvironment of a wide range of solid tumors and largely absent from normal adult tissues. MICVO is designed to treat solid tumors through a three-pronged mechanism of action: direct cancer cell killing, bystander effect and immunogenic cell death. MICVO is currently being evaluated as monotherapy in a Phase 1 clinical study in patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) and in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in a Phase 1/2 clinical study in patients with R/M HNSCC and other solid tumors. Pyxis Oncology is focused on advancing MICVO, with the goal of improving outcomes for patients living with R/M HNSCC and contributing to meaningful progress in cancer treatment.
MICVO received Fast Track Designation from the U.S. Food and Drug Administration for the treatment of adult patients with R/M HNSCC whose disease has progressed following treatment with platinum-based chemotherapy and an anti-PD-(L)1 therapy.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
To learn more, visit
www.pyxisoncology.com
or follow us on
.
Pyxis Oncology Contact
IR@pyxisoncology.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。